✦ LIBER ✦

A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma

✍ Scribed by Li, Ning; Ou, Wei; Yang, Hua; Liu, Qian-Wen; Zhang, Song-Liang; Wang, Bao-Xiao; Wang, Si-Yu

Book ID: 127391195
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 229 KB
Volume: 120
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.28591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pemetrexed versus gefitinib as a second-

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial

✍ Zhou, Q.; Cheng, Y.; Yang, J.- J.; Zhao, M.- F.; Zhang, L.; Zhang, X.- C.; Chen, 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 228 KB

Erlotinib versus docetaxel as second-lin

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

✍ Garassino, Marina Chiara; Martelli, Olga; Broggini, Massimo; Farina, Gabriella; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 279 KB

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB

LUX-lung 3: A randomized, open-label, ph

LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations

✍ Schuler, Martin; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O’Byrne, Ken; Hirsh, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Pemetrexed Versus Pemetrexed and Carbopl

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

✍ Ardizzoni, A.; Tiseo, M.; Boni, L.; Vincent, A. D.; Passalacqua, R.; Buti, S.; A 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 200 KB

A multicenter, nonrandomized, open-label

A multicenter, nonrandomized, open-label, single-arm phase 2 trial of dovitinib (TKI258) as second-line therapy in patients with fibroblast growth factor receptor 2-mutated or wild-type advanced and/or metastatic endometrial cancer

✍ G. Konecny; N. Finkler; P. Lee; A. Yovine; A. Liu; P. Sen; M. Squires; A. Kay 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB